drugset

drugset / Trial / NCT06334133

Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes

NCT06334133 ↗

Phase 3 Recruiting 150 enrolled vTv Therapeutics

RandomizedParallel-groupTriple-blindTreatment

Summary

This is a Phase 3 trial of cadisegliatin as adjunctive therapy to insulin in participants with Type 1 Diabetes Mellitus.

Timeline

Start: 2024-06-14
Primary completion: 2026-09
Completion: 2026-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cadisegliatin	Small molecule	800 mg	Oral

Indications